Exact Sciences Corp.
https://www.exactsciences.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exact Sciences Corp.
PAVmed Plans Spin-Off And Marketing Push For Lucid Diagnostics
Lucid, which markets the EsoGuard test for Barrett’s esophagus, will become a separate public company, either through an IPO or a business combination with a health care SPAC.
Exact Sciences Acquires Ashion Analytics To Accelerate Sequencing Technology
The addition of the Arizona-based sequencing lab builds on Exact’s recent license of the TARDIS liquid biopsy technology from TGen.
Guardant Health Launches Liquid Biopsy Test For Detecting Colorectal Cancer Recurrence
Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.
Pandemic Leaves Medtech With $500bn In M&A Firepower
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
Company Information
- Industry
- Biotechnology
- Laboratory Testing Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Base Genomics
- Genomic Health, Inc.
- Paradigm Diagnostics, Inc.
- Thrive Earlier Detection Corp.
- Viomics, Inc.